KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Amgen (AMGN) over the last 17 years, with Q4 2025 value amounting to $9.1 billion.

  • Amgen's Cash & Equivalents fell 2375.34% to $9.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $9.1 billion, marking a year-over-year decrease of 2375.34%. This contributed to the annual value of $9.1 billion for FY2025, which is 2375.34% down from last year.
  • According to the latest figures from Q4 2025, Amgen's Cash & Equivalents is $9.1 billion, which was down 2375.34% from $9.4 billion recorded in Q3 2025.
  • In the past 5 years, Amgen's Cash & Equivalents registered a high of $34.7 billion during Q3 2023, and its lowest value of $5.2 billion during Q2 2022.
  • Moreover, its 5-year median value for Cash & Equivalents was $9.2 billion (2024), whereas its average is $12.4 billion.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first surged by 55823.56% in 2023, then crashed by 7406.23% in 2024.
  • Quarter analysis of 5 years shows Amgen's Cash & Equivalents stood at $8.0 billion in 2021, then fell by 4.51% to $7.6 billion in 2022, then skyrocketed by 43.45% to $10.9 billion in 2023, then grew by 9.4% to $12.0 billion in 2024, then decreased by 23.75% to $9.1 billion in 2025.
  • Its Cash & Equivalents was $9.1 billion in Q4 2025, compared to $9.4 billion in Q3 2025 and $8.0 billion in Q2 2025.